MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

MC

499.05

-0.27%↓

NDA.FI

11.82

+1.37%↑

DIM

202.2

+0.45%↑

Search

Grifols SA

Ouvert

SecteurFinance

8.466 0.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

8.42

Max

8.564

Chiffres clés

By Trading Economics

Revenu

17M

69M

Ventes

183M

2B

P/E

Moyenne du Secteur

36.313

20.525

BPA

0.101

Marge bénéficiaire

3.491

Employés

23,833

EBITDA

57M

482M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+65.92% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.6B

5.2B

Ouverture précédente

8.09

Clôture précédente

8.466

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Grifols SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 avr. 2025, 17:19 UTC

Acquisitions, Fusions, Rachats

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 avr. 2025, 13:02 UTC

Acquisitions, Fusions, Rachats

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 avr. 2025, 10:13 UTC

Acquisitions, Fusions, Rachats

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 juil. 2024, 10:40 UTC

Acquisitions, Fusions, Rachats

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 juil. 2024, 09:13 UTC

Acquisitions, Fusions, Rachats

Grifols Faces Delisting Bid From Founding Family and Brookfield

15 avr. 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 avr. 2025, 09:27 UTC

Actions en Tendance

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparaison

Variation de prix

Grifols SA prévision

Objectif de Prix

By TipRanks

65.92% hausse

Prévisions sur 12 Mois

Moyen 14.02 EUR  65.92%

Haut 19.05 EUR

Bas 11 EUR

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

3 ratings

2

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.006 / 8.544Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.